Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Inventiva S.A. Sponsored ADR (IVA : NSDQ)
 
 • Company Description   
Inventiva S.A. is a clinical-stage biopharmaceutical company. It is focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need. Inventiva S.A. is based in Daix, France.

Number of Employees: 113

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.85 Daily Weekly Monthly
20 Day Moving Average: 48,318 shares
Shares Outstanding: 42.13 (millions)
Market Capitalization: $162.22 (millions)
Beta: 0.98
52 Week High: $9.31
52 Week Low: $2.22
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 30.28% 25.35%
12 Week -16.30% -22.31%
Year To Date -13.68% -21.48%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
50 RUE DE DIJON
-
DAIX,I0 21121
FRA
ph: 33-3-80-44-75-00
fax: -
finance@inventivapharma.com http://www.inventivapharma.com
 
 • General Corporate Information   
Officers
Frederic Cren - Chief Executive Officer and Chairman
Jean Volatier - Chief Financial Officer
Chris Buyse - Director
Lucy Lu - Director
Heinz Maeusli - Director

Peer Information
Inventiva S.A. Sponsored ADR (CORR.)
Inventiva S.A. Sponsored ADR (RSPI)
Inventiva S.A. Sponsored ADR (CGXP)
Inventiva S.A. Sponsored ADR (BGEN)
Inventiva S.A. Sponsored ADR (GTBP)
Inventiva S.A. Sponsored ADR (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 46124U107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: -
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding: 42.13
Most Recent Split Date: (:1)
Beta: 0.98
Market Capitalization: $162.22 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.63 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.95 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.39
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/23 - -
12/31/22 - -
09/30/22 - -
ROA
03/31/23 - -
12/31/22 - -
09/30/22 - -
Current Ratio
03/31/23 - -
12/31/22 - 3.47
09/30/22 - -
Quick Ratio
03/31/23 - -
12/31/22 - 3.45
09/30/22 - -
Operating Margin
03/31/23 - -
12/31/22 - -
09/30/22 - -
Net Margin
03/31/23 - -
12/31/22 - -
09/30/22 - -
Pre-Tax Margin
03/31/23 - -
12/31/22 - -288.59
09/30/22 - -
Book Value
03/31/23 - -
12/31/22 - 1.14
09/30/22 - -
Inventory Turnover
03/31/23 - -
12/31/22 - 0.00
09/30/22 - -
Debt-to-Equity
03/31/23 - -
12/31/22 - 0.63
09/30/22 - -
Debt-to-Capital
03/31/23 - -
12/31/22 - 38.66
09/30/22 - -
 

Powered by Zacks Investment Research ©